Download Info Pack
Why Cordlife
About Cordlife


  • 2001

    CordLife Pte Ltd established and licensed by Ministry of Health (MOH) Singapore

  • 2002

    First cord blood released for sibling-use.

    Laboratory at Camden Medical Centre opened for public viewing.

  • 2005

    Received accreditation from American Association of Blood Banks (AABB)

    AABB's Accreditation Program strives to improve the quality and safety of collecting, processing, testing, distributing and administering blood and blood products by assessing the quality and operational systems in place within the facility.

    Offered Medicord, a stem cell transplant insurance programme.

    Entered Hong Kong and People's Republic of China (PRC) markets.

  • 2007

    Expanded to new Science Park II facility.

    Cordlife Hong Kong achieved ISO:9001.

  • 2008

    Re-accredited by American Association of Blood Banks (AABB).

    Launch of automated processing system to maximise recovery of cells for transplant use.

  • 2009

    Re-accredited by American Association of Blood Banks (AABB).

    First-ever release of autologous cord blood for Cerebral Palsy

    Launched Cordlife Quality Guarantee, a warranty to protect Cordlife clients.

    Introduction of SepaxTM, the only fully automated cord blood processing technology , to Singapore and Hong Kong.

  • 2010

    First-ever release of autologous cord blood for Neuroblastoma.

    Released autologous cord blood for Cerebral Palsy.

    Cordlife has been voted as the most trust worthy cord blood bank by the private O&G specialists in Hong Kong.

  • 2011

    CordLife Pte Ltd renamed to "Cordlife Group Limited".

    Launched Cordlife Care360° Safeguard programme.

    Re-accredited by American Association of Blood Banks (AABB).

    Launched provision of umbilical cord tissue banking services in Hong Kong.

    Hong Kong facility accredited by American Association of Blood Banks (AABB)

  • 2012

    Successfully listed on Singapore Exchange Main Board on 29 March 2012.

    More than 40,000 clients stored their precious stem cells with Cordlife.

  • 2013

    Cordlife Group successfully acquired majority stake in StemLife, No.1 cord blood bank in Malaysia.

    First private cord blood bank in Singapore to launch automated processing system to facilitate the optimisation of cord blood stem cells for maximum transplant success*.

    Cordlife Hong Kong was successfully accredited by AABB and ISO again, and we have powered up to Sepax®2.

    Cordlife Group formed its subsidiaries in India, the Philippines and Indonesia.

    Awarded 'Most Transparent Company Award' by SIAS Investors Choice

  • 2014

    Launched CellOptimaTM Umbilical Cord Lining Cells expansion and storage services which can expand to 5000 millions cells, the largest amount of expanded cells in Hong Kong.

    Cordlife Hong Kong launched MetascreenTM newborn screening program, checking over 100 inborn errors of metabolism for babies from one simple urine test.

    Assisted autistic children in Hong Kong to participate in groundbreaking Duke Medicine Programme to validate usage of cord blood stem cells in treatment of autism and other brain disorders.

  • 2015

    Launched exclusive cord blood transplant care for Cordlife families who need autologous cord blood transplant treatments.

    Cordlife Hong Kong maintains ISO and received AABB reaccreditation for the 5th time.

    Cordlife Group Limited received accreditation from FACT which ensures the global standard of excellence in patient care and laboratory practices.

    Honoured by Forbes Asia as one of the "Best Under a Billion" companies in November 2015.

    Acquired the first and largest cord blood bank in Malaysia, Stemlife Berhad as one of its subsidiaries.

  • 2016

    First Singapore-based cord blood bank to launch in Myanmar and Vietnam.

    Received Accreditation from College of American Pathologists for its Hong Kong and India Subsidiaries.

    Cordlife Hong Kong was successfully accredited by AABB again.

  • 2017

    Awarded “Top 10 Family Brand Award” by Baby Kingdom

    More than 56,000 parents stored their child's precious stem cells with Cordlife.

    Launched Cordlife’s first-ever public "Cordlife Donation Drive" in Singapore and raised both cash and donations-in-kind for Singapore Children’s Society.

  • 2018

    Awarded "Best Family Cord Blood Bank Award" by Mummys Market.

    More than 60,000 parents stored their child’s precious stem cells with Cordlife.

  • 2019

    Officially opened the largest full-fledged cord blood and tissue banking facility in Indonesia.

    Appointed marketing agent in Bangladesh, one of the fastest growing economies of the world.

    Cordlife Philippines received re-accreditation from AABB and remains the only AABB accredited facility in the country.

    Cordlife Indonesia’s facility became the first and only in Indonesia to receive AABB accreditation.

  • 2020

    Cordlife Indonesia launched PreImplantation Genetic Screening to help improve the likelihood of a successful pregnancy of couples undergoing in vitro fertilisation (“IVF”) treatment. They subsequently launched Genelife, a lifestyle genetic testing and Umbilical Cord Wharton’s Jelly banking service.

    Cordlife Hong Kong launched paediatric allergy testing to detect up to 104 allergens; bebegene®, a newborn genetic screening with comprehensive assessment of more than 120 genetic related diseases in infants and children aged 0-3; and LifeScreen, a talent genetic test panel for children.

    Cordlife Philippines celebrated the inauguration of new Cordlife satellite offices in St. Luke’s Medical Center Quezon City, Cebu City, and Davao City

    Stemlife Malaysia launched non-invasive prenatal testing in Malaysia.

  • 2021

    Cordlife embarked on a digital transformation journey to change how the Group goes digital to better impact, externally for clients and internally for employees.

    Cordlife Singapore and Cordlife Hong Kong launched OptiQ, a first-of-its-kind corneal lenticule banking service.

    Cordlife Singapore partnered with SingHealth Duke-NUS Academic Medical Centre to advance stem cell technology to a first in-man clinical trial in Singapore. In addition, Cordlife Singapore also launched Moms Up, a one-stop solution app that provides localised advice on conceiving, pregnancy, and postpartum support for women in Singapore.

    Stemlife Malaysia received The BrandLaureate World’s e-Branding Award – Best Brand of the Year 2020 in Innovation Stem Cell Solutions, from The World Brands Foundation. Stemlife Malaysia also launched Bebegene, a newborn genetic screening service.

    Cordlife Hong Kong launched Cordlife Carrier Screening, Cordlife Hereditary Cancer Screening, Cordlife Hereditary Cardiac Disease Screening and Cordlife Hereditary Neurological Disease Screening.

    Cordlife Hong Kong and Cordlife Indonesia launched MIRA, a miRNA-based receptivity analysis testing to help couples undergoing IVF in determining the best time for embryo transfer to increase their chance of pregnancy.

    Cordlife Hong Kong, Cordlife Indonesia and Cordlife Philippines launched Cordlife Alliance, a community banking programme that allows Cordlife’s clients to help another Cordlife family in need of a cord blood unit.

    Cordlife India launched in-house diagnostic services.

    Cordlife India attained NABL accreditation for the first time

*Conditions apply.